1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pathology Analysis & Statistics

Pathology Analysis & Statistics

1-30 of about 200 reports

Hepatitis Viruses Rapid Tests and POC - Medical Devices Pipeline Product Landscape, 2021

  • $ 2500
  • October 2021
  • 46 pages

Hepatitis Viruses Rapid Tests and POC - Medical Devices Pipeline Product Landscape, 2021 Summary Medical Devices sector report, “Hepatitis Viruses Rapid Tests and POC - Medical Devices Pipeline Product ...

  • World
  • Hepatitis
  • Diagnostics
  • Company research
  • Company
  • Interest Payments Paid By Central Government
  • Medical Devices Sales

Drug Addiction (Central Nervous System) - Drugs In Development, 2021

  • $ 2000
  • June 2021
  • 258 pages

Drug Addiction (Central Nervous System) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction (Central Nervous System) - Drugs In Development, ...

  • World
  • United States
  • Addiction Disorder
  • Drug Development
  • Investor presentation
  • Company
  • Drug Approval
  • Illicit Drug Use

EU5 Trauma Fixation Market Outlook to 2025 - External Fixators and Internal Fixators

  • $ 5995
  • February 2021
  • 135 pages

EU5 Trauma Fixation Market Outlook to 2025 - External Fixators and Internal Fixators Summary “EU5 Trauma Fixation Market Outlook to 2025” is a comprehensive databook report, covering key market ...

  • Europe
  • United Kingdom
  • Orthopedics
  • Infectious Disease
  • Investor presentation
  • Company
  • Medical Technology Density
  • Direct Sales

Company Analysis: Ono Pharmaceutical

  • $ 3000
  • January 2021
  • 87 pages

PharmaVitae explores Ono Pharmaceutical’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Ono Pharmaceutical’s revenue is largely dependent on the performance ...

  • Japan
  • Prescription Drug
  • Colorectal Cancer
  • Company research
  • Company

Company Analysis: Takeda

  • $ 3000
  • January 2021
  • 62 pages

PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Takeda’s growth continues to be driven primarily by MandA; adding Shire ...

  • United States
  • Prescription Drug
  • Digestive System Disorder
  • Company research
  • Company

Company Analysis: Shionogi

  • $ 3000
  • January 2021
  • 40 pages

PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029. Snapshot Overview – PharmaVitae forecasts Shionogi’s revenue to remain flat through 2029, ...

  • Japan
  • United States
  • Prescription Drug
  • Influenza
  • Company research
  • Company

Company Analysis: Eisai

  • $ 3000
  • January 2021
  • 53 pages

PharmaVitae explores Eisai’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Eisai’s growth will continue to be driven by Lenvima in the mid-term, with ...

  • China
  • Dementia
  • Prescription Drug
  • Company research
  • Company

Company Analysis: Astellas

  • $ 3000
  • January 2021
  • 45 pages

PharmaVitae explores Astellas’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Astellas is forecast to grow revenue until 2026, at which point flagship ...

  • United States
  • Europe
  • Prostate Cancer
  • Company research
  • Company

Company Analysis: Vertex

  • $ 3000
  • January 2021
  • 43 pages

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Vertex is making impressive progress with its newly launched and late-stage ...

  • United States
  • Cystic Fibrosis
  • Company research
  • Company

Company Analysis: Johnson & Johnson

  • $ 3000
  • January 2021
  • 62 pages

PharmaVitae explores Johnson and Johnson’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Johnson and Johnson’s growth will be driven by its pharmaceuticals ...

  • United States
  • Pharmaceutical
  • Prescription Drug
  • Company research
  • Company

Company Analysis: Lundbeck

  • $ 3000
  • January 2021
  • 39 pages

PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Lundbeck’s prescription pharmaceutical sales are set to grow over the ...

  • World
  • Prescription Drug
  • Bipolar Disorder
  • Company research
  • Company

Company Analysis: Gilead

  • $ 3000
  • January 2021
  • 67 pages

PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Gilead’s sales will remain broadly stable over the medium term due to its ...

  • United States
  • Europe
  • Prescription Drug
  • Autoimmune Disease
  • Company research
  • Company

Company Analysis: Teva

  • $ 3000
  • January 2021
  • 41 pages

PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Teva will look to build on the launches of Austedo and Ajovy to counter the ...

  • North America
  • United States
  • Neurological Disorder
  • Dementia
  • Company research
  • Company

Company Analysis: Sanofi

  • $ 3000
  • January 2021
  • 69 pages

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Sanofi will see strong pharmaceutical revenue growth over the forecast period, ...

  • United States
  • Pharmaceutical
  • Respiratory Disease
  • Company research
  • Company
  • Pharmaceutical Revenue

Company Analysis: Roche

  • $ 3000
  • January 2021
  • 97 pages

PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Roche is poised to grow despite significant biosimilar headwinds to legacy ...

  • United States
  • Biosimilar
  • Lung Cancer
  • Company research
  • Company

Company Analysis: Novo Nordisk

  • $ 3000
  • January 2021
  • 64 pages

PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Novo Nordisk continues to dominate the diabetes segment, but pricing ...

  • United States
  • Insulin
  • Diabetes
  • Company research
  • Company

Company Analysis: Novartis

  • $ 3000
  • January 2021
  • 85 pages

PharmaVitae explores Novartis’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Novartis’s strong launch portfolio will drive robust revenue growth ove ...

  • United States
  • Neurological Disorder
  • Company research
  • Company

Company Analysis: Bristol-Myers Squibb

  • $ 3000
  • January 2021
  • 95 pages

PharmaVitae explores Bristol Myers Squibb’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Bristol Myers Squibb’s acquisition of Celgene meaningfully ...

  • United States
  • Lung Cancer
  • Renal Cancer
  • Company research
  • Company

Company Analysis: AstraZeneca

  • $ 3000
  • January 2021
  • 87 pages

PharmaVitae explores AstraZeneca’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – AstraZeneca is poised for continued growth, driven by its oncology portfolio ...

  • World
  • China
  • Lung Cancer
  • Prescription Drug
  • Company research
  • Company

Company Analysis: Biogen

  • $ 3000
  • January 2021
  • 45 pages

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Biogen’s prescription pharmaceutical business will see stable performance ...

  • United States
  • Prescription Drug
  • Dementia
  • Company research
  • Company

Company Analysis: Regeneron

  • $ 3000
  • January 2021
  • 53 pages

PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Regeneron’s prescription pharmaceutical business has solid near-term ...

  • United States
  • Prescription Drug
  • Cancer
  • Company research
  • Company

Company Analysis: UCB

  • $ 3000
  • January 2021
  • 38 pages

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – UCB will experience impressive growth of its core portfolio of CNS and IandI ...

  • Europe
  • Prescription Drug
  • Clinical Trial
  • Company research
  • Company

Neuroblastoma - Pipeline Review, H2 2020

  • $ 2500
  • November 2020
  • 1084 pages

Neuroblastoma - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H2 2020, provides an overview of the Neuroblastoma (Oncology) ...

  • World
  • Cancer
  • Therapy
  • Company research
  • Company

Prostate Cancer - Pipeline Review, H2 2020

  • $ 2500
  • November 2020
  • 3323 pages

Prostate Cancer - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H2 2020, provides an overview of the Prostate Cance ...

  • World
  • Prostate Cancer
  • Company research
  • Company

Obesity - Pipeline Review, H2 2020

  • $ 2500
  • November 2020
  • 640 pages

Obesity - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2020, provides an overview of the Obesity (Metabolic Disorders) ...

  • World
  • Endocrine Disease
  • Obesity
  • Company research
  • Company

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2020

  • $ 2500
  • November 2020
  • 1581 pages

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia - Pipeline Review, H2 2020, provides an ...

  • World
  • Leukemia
  • Company research
  • Company

Type 2 Diabetes - Pipeline Review, H2 2020

  • $ 2500
  • November 2020
  • 1251 pages

Type 2 Diabetes - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H2 2020, provides an overview of the Type 2 Diabetes ...

  • World
  • Type 2 Diabetes
  • Endocrine Disease
  • Company research
  • Company

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020

  • $ 2500
  • November 2020
  • 868 pages

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020, provides an overview ...

  • World
  • Dementia
  • Neurology
  • Company research
  • Company

Non-Hodgkin Lymphoma - Pipeline Review, H2 2020

  • $ 2500
  • November 2020
  • 3999 pages

Non-Hodgkin Lymphoma - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2020, provides an overview of the Non-Hodgkin ...

  • World
  • Lymphoma
  • Company research
  • Company

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2020

  • $ 2500
  • November 2020
  • 733 pages

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes - Pipeline Review, H2 2020, provides an overview of ...

  • World
  • Type 1 Diabetes
  • Endocrine Disease
  • Company research
  • Company
About 16000 reports

Download Unlimited Documents from Trusted Public Sources

View report >

CF Industries Investor presentation

  • January 2022
  • 4 pages
  • United States
  • Fertilizer
  • Agrochemical
  • Investor presentation
  • Company
  • Natural Gas Price
  • Greenhouse Gas Emissions

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on